Synthesis of 24,24-ethanovitamin D3 lactones using ruthenium-catalyzed intermolecular enyne metathesis: Potent vitamin D receptor antagonists

Synthesis

Volumn , Issue 15, 2005, Pages 2533-2543

  Saito, Nozomi ^a   Masuda, Manami ^a   Saito, Hiroshi ^b   Takenouchi, Kazuya ^b   Ishizuka, Seiichi ^b   Namekawa, Jun Ichi ^b   Takimoto Kamimura, Midori ^b   Kittaka, Atsushi ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIJIN LTD   (Japan)

Author keywords

Antagonist; Enynes; Lactones; Metathesis; Ruthenium; Vitamins

Indexed keywords

CATALYSIS; CELLS; ENZYMES; PALLADIUM; RUTHENIUM; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL);

ANTAGONIST; LACTONES; METATHESIS; PRECURSORS;

VITAMINS;

24,24 ETHANO ALPHA METHYLENE GAMMA LACTONE; 24,24 ETHANOCOLECALCIFEROL 26,23 LACTONE DERIVATIVE; 24,24 ETHANOCOLECALCIFEROL LACTONE DERIVATIVE; 25 DEHYDRO 24,24 ETHANO 1ALPHA HYDROXYCOLECALCIFEROL 26,23 LACTONE; 25 DEHYDRO 24,24 ETHANO 2ALPHA METHYL 1ALPHA HYDROXYCOLECALCIFEROL 26,23 LACTONE; 25 DEHYDRO 24,24 ETHANO 2ALPHA(3 HYDROXYPROPOXYL) 1ALPHA HYDROXYCOLECALCIFEROL 26,23 LACTONE; 25 DEHYDRO 24,24 ETHANO 2ALPHA(3 HYDROXYPROPYL) 1ALPHA HYDROXYCOLECALCIFEROL 26,23 LACTONE; 3 BENZOYLOXY 4 OXYRANYLBUT 1 ENE; 3 HYDROXYPROPOXYL DERIVATIVE; 3 HYDROXYPROPYL DERIVATIVE; 4 BENZOYLOXY 5 HEXENE 1,2 DIOL; 6 (4 BROMOMETHYLENE 7A METHYLOCTAHYDROINDEN 1 YL) 1 (TERT BUTYLDIMETHYLSILYLOXY)HEPT 2 YN 4 ONE; 6 (4 BROMOMETHYLENE 7A METHYLOCTAHYDROINDEN 1 YL) 2 [(TERT BUTYLDIMETHYLSILYLOXY)METHYL] 3 METHYLENEHEPT 1 EN 4 ONE; ALKENE; ALKENYL GROUP; BIS(TERT BUTYLDIMETHYLSILYLOXY)OCT 1 EN 7 YNE; BROMINE; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; ETHYLENE; HYDROXYL GROUP; LACTONE DERIVATIVE; METHYL GROUP; PROPANE; RECEPTOR BLOCKING AGENT; RUTHENIUM; TEI 9647; TEI 9648; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR BLOCKING AGENT;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYST; CELL STRAIN HL 60; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; CYCLOPROPANATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; IC 50; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; RECEPTOR BLOCKING; RING CLOSING METATHESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 26844575469     PISSN: 00397881     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872075     Document Type: Article

References (57)

1. (a) Vitamin D; Feldman, D.; Glorieux, F. H.; Pike, J. W., Eds.; Academic Press: New York, 1997.
2. (b) Ettinger, R. A.; DeLuca, H. F. Adv. Drug Res. 1996, 28, 269.
3. Bouillon, R.; Okamura, W. H.; Norman, A. W. Endocr. Rev. 1995, 16, 200.
4. (a) Evans, R. M. Science 1988, 240, 889.
5. (b) Umezono, K.; Murakami, K. K.; Thompson, C. C.; Evans, R. M. Cell 1991, 65, 1255.
6. Takeyama, K.; Masuhiro, Y.; Fuse, H.; Endoh, H.; Murayama, A.; Kitanaka, S.; Suzawa, M.; Yanagisawa, J.; Kato, S. Mol. Cell Biol. 1999, 19, 1049.
7. (a) Konno, K.; Maki, S.; Fujishima, T.; Liu, Z.; Miura, D.; Chokki, M.; Takayama, H. Bioorg. Med. Chem. Lett. 1998, 8, 151.
8. (b) Konno, K.; Fujishima, T.; Maki, S.; Liu, Z.; Miura, D.; Chokki, M.; Ishizuka, S.; Yamaguchi, K.; Kan, Y.; Kurihara, M.; Miyata, N.; Smith, C.; DeLuca, H. F.; Takayama, H. J. Med. Chem. 2000, 43, 4247.
9. (a) Suhara, Y.; Nihei, K.; Tanigawa, H.; Fujishima, T.; Konno, K.; Nakagawa, K.; Okano, T.; Takayama, H. Bioorg. Med. Chem. Lett. 2000, 10, 1129.
10. (b) Suhara, Y.; Nihei, K.; Kurihara, M.; Kittaka, A.; Yamaguchi, K.; Fujishima, T.; Konno, K.; Miyata, N.; Takayama, H. J. Org. Chem. 2001, 66, 8760.
11. (a) Kittaka, A.; Suhara, Y.; Takayanagi, H.; Fujishima, T.; Kurihara, M.; Takayama, H. Org. Lett. 2000, 2, 2619.
12. (b) Saito, N.; Suhara, Y.; Kurihara, M.; Fujishima, T.; Honzawa, S.; Takayanagi, H.; Kozono, T.; Matsumoto, M.; Ohmori, M.; Miyata, N.; Takayama, H.; Kittaka, A. J. Org. Chem. 2004, 69, 7463.
13. For our account, see: Takayama, H.; Kittaka, A.; Fujishima, T.; Suhara, Y. Vitamin D Analogs in Cancer Prevention and Therapy, Recent Results in Cancer Research, Vol. 164; Reichrath, J.; Friedrich, M.; Tilgen, W., Eds.; Springer-Verlag: Berlin, 2003, 289.
14. 3, see: (a) Ono, K.; Yoshida, A.; Saito, N.; Fujishima, T.; Honzawa, S.; Suhara, Y.; Kishimoto, S.; Sugiura, T.; Waku, K.; Takayama, H.; Kittaka, A. J. Org. Chem. 2003, 68, 7407.
15. (b) Yoshida, A.; Ono, K.; Suhara, Y.; Saito, N.; Takayama, H.; Kittaka, A. Synlett 2003, 1175.
16. (a) Miura, D.; Manabe, K.; Ozono, K.; Saito, M.; Gao, Q.; Norman, A. W.; Ishizuka, S. J. Biol. Chem. 1999, 274, 16392.
17. (b) Ozono, K.; Saito, M.; Miura, D.; Michigami, T.; Nakajima, S.; Ishizuka, S. J. Biol. Chem. 1999, 274, 32376.
18. (c) Miura, D.; Manabe, K.; Gao, Q.; Norman, A. W.; Ishizuka, S. FEBS Lett. 1999, 460, 297.
19. (d) Ishizuka, S.; Miura, D.; Eguchi, H.; Ozono, K.; Chokki, M.; Kamimura, T.; Norman, A. W. Arch. Biochem. Biophys. 2000, 380, 92.
20. (e) Ishizuka, S.; Miura, D.; Ozono, K.; Chokki, M.; Mimura, H.; Norman, A. W. Endocrinol. 2001, 142, 59.
21. (f) Ishizuka, S.; Miura, D.; Ozono, K.; Saito, M.; Eguchi, H.; Chokki, M.; Norman, A. W. Steroids 2001, 66, 227.
22. For a recent report on the other type of VDR antagonist of 25-carboxylic esters ZK159222 and ZK168281, see: Väisänen, S.; Peräkylä, M.; Kärkkäinen, J. I.; Steinmeyer, A.; Carlberg, C. J. Mol. Biol. 2002, 375, 229.
23. (a) Ishizuka, S.; Ishimoto, S.; Norman, A. W. Biochemistry 1984, 23, 1473.
24. (b) Ishizuka, S.; Ohba, T.; Norman, A. W. Vitamin D: Molecular, Cellular and Chemical Endocrinology; Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; von Herrath, D., Eds.; Walter de Gruyter: Berlin, 1988, 143.
25. (a) Carlberg, C. J. Cell. Biochem. 2003, 88, 274.
26. (b) Toell, A.; Gonzalez, M. M.; Ruf, D.; Steinmeyer, A.; Ishizuka, S.; Carlberg, C. Mol. Pharmacol. 2001, 59, 1478.
27. (a) Saito, N.; Matsunaga, T.; Fujishima, T.; Anzai, M.; Saito, H.; Takenouchi, K.; Miura, D.; Ishizuka, S.; Takayama, H.; Kittaka, A. Org. Biomol. Chem. 2003, 1, 4396.
28. (b) Saito, N.; Saito, H.; Anzai, M.; Yoshida, A.; Fujishima, T.; Takenouchi, K.; Miura, D.; Ishizuka, S.; Takayama, H.; Kittaka, A. Org. Lett. 2003, 5, 4859.
29. (c) Saito, N.; Masuda, M.; Matsunaga, T.; Saito, H.; Anzai, M.; Takenouchi, K.; Miura, D.; Ishizuka, S.; Takimoto-Kamimura, M.; Kittaka, A. Tetrahedron 2004, 60, 7951.
30. Wiggins, L. S. Methods Carbohydr. Chem. 1963, 2, 181.
31. Taillefumier, C.; Chapleur, Y. Can. J. Chem. 2000, 78, 708.
32. Previously, the enyne 12 was prepared through Sharpless asymmetric dihydroxylation of 3-butenyl 4-methoxyphenyl ether: Fujishima, T.; Konno, K.; Nakagawa, K.; Kurobe, M.; Okano, T.; Takayama, H. Bioorg. Med. Chem. 2000, 8, 123.
33. The original works of Ru-catalyzed intermolecular enyne metathesis, see: Kinoshita, A.; Sakakibara, N.; Mori, M. J. Am. Chem. Soc. 1997, 119, 12388.
34. (a) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953.
35. (b) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2000, 122, 8168.
36. (c) Wakamatsu, H.; Blechert, S. Angew. Chem. Int. Ed. 2002, 41, 2403.
37. (d) instability of 15 and 16d at r.t. would cause low yield of 17 and low recovery of 15.
38. 3, R1 = 0.063 for 16610 reflections [I > 3.00s (I)], wR2 = 0.068 [I > 3.00s (I)]; structure solution and refinement were performed using Direct Methods (SIR92) and full-matrix least-squares on F, respectively. Diffractometer Rigaku RAXIS-RAPID, graphite monochlomated CuKα (λ = 1.54187 Å).
39. Trost, B. M.; Dumas, J.; Villa, M. J. Am. Chem. Soc. 1992, 114, 9836.
40. (a) Eisman, J. A.; Hamstra, A. J.; Kream, B. E.; DeLuca, H. F. Arch. Biochem. Biophys. 1976, 176, 235.
41. (b) Inaba, M.; DeLuca, H. F. Biochim. Biophys. Acta 1989, 1010, 20.
42. Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo, R. C. J. Exp. Med. 1979, 149, 969.
43. (a) Suhara, Y.; Kittaka, A.; Kishimoto, S.; Calverly, M. J.; Fujishima, T.; Saito, N.; Sugiura, T.; Waku, K.; Takayama, H. Bioorg. Med. Chem. Lett. 2002, 12, 3255.
44. (b) Honzawa, S.; Yamamoto, Y.; Hirasaka, K.; Takayama, H.; Kittaka, A. Heterocycles 2003, 61, 327.
45. (c) Honzawa, S.; Suhara, Y.; Nihei, K.; Saito, N.; Kishimoto, S.; Fujishima, T.; Kurihara, M.; Sugiura, T.; Waku, K.; Takayama, H.; Kittaka, A. Bioorg. Med. Chem. Lett. 2003, 13, 3503.
46. For an excellent description of the VDR-generated transactivation mechanism, see: Masuno, H.; Yamamoto, K.; Wang, X.; Choi, M.; Ooizumi, H.; Shinki, T.; Yamada, S. J. Med. Chem. 2002, 45, 1825.
47. Recent reviews on the function of VDR in response to 1 and other synthetic ligands, see: (a) Carlberg, C. In Vitamin D Analogs in Cancer Prevention and Therapy, Recent Results in Cancer Research, Vol. 164; Reichrath J., Friedrich M., Tilgen M., Eds., Springer: Berlin, 2003, 29.
48. (b) Carlberg, C. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 227; see also ref. 13.
49. Bula, C. M.; Bishiop, J. E.; Ishizuka, S.; Norman, A. W. Mol. Endocrinol. 2000, 14, 1788.
50. (a) Ochiai, E.; Miura, D.; Eguchi, H.; Takenouchi, K.; Harada, Y.; Azuma, Y.; Kamimura, T.; Ishizuka, S. J. Bone. Miner. Res. 2003, 18 (suppl. 2), S103.
51. (b) Ochiai, E.; Miura, D.; Eguchi, H.; Ohara, S.; Takenouchi, K.; Harada, Y.; Azuma, Y.; Kamimura, T.; Norman, A. W.; Ishizuka, S. Mol. Endocrinol. 2005, 19, 1147.
52. Peräkylä, M.; Molnár, F.; Carlberg, C. Chem. Biol. 2004, 11, 1147.
53. Takenouchi, K.; Sogawa, R.; Manabe, K.; Saitoh, H.; Gao, Q.; Miura, D.; Ishizuka, S. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 31.
54. It is well known that some biologically active natural products having an α-methylene-γ-lactone structure react with the thiol group of cysteine to give the corresponding cysteine adduct: Kupchan, S. M.; Fessier, D. C.; Eakin, M. A.; Giacobbe, T. J. Science 1970, 168, 376.
55. For recent reviews on Paget's bone disease, see: (a) Reddy, S. V. J. Cell Biochem. 2004, 93, 688.
56. (b) Roodman, G. D.; Windle, J. J. J. Clin. Invest. 2005, 115, 200.
57. Wender, P. A.; Sieburth, S. McN.; Petraitis, J. J.; Singh, S. K. Tetrahedron 1981, 37, 1967.